Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:UPSA
|
| gptkbp:acquisitionYear |
2019
|
| gptkbp:CEO |
gptkb:Shigeru_Uehara
|
| gptkbp:country |
gptkb:Japan
|
| gptkbp:founded |
1912
|
| gptkbp:founder |
gptkb:Uehara_family
|
| gptkbp:headquarters_location |
gptkb:Tokyo
|
| https://www.w3.org/2000/01/rdf-schema#label |
Taisho Pharmaceutical
|
| gptkbp:industry |
pharmaceuticals
consumer healthcare |
| gptkbp:logo |
Taisho Pharmaceutical logo.svg
|
| gptkbp:nativeName |
gptkb:大正製薬株式会社
|
| gptkbp:notableProduct |
gptkb:Colac
gptkb:Zena gptkb:Lipovitan_D gptkb:Pabron |
| gptkbp:numberOfEmployees |
6,400
|
| gptkbp:officialWebsite |
https://www.taisho.co.jp/en/
|
| gptkbp:parentCompany |
gptkb:Taisho_Pharmaceutical_Holdings_Co.,_Ltd.
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:revenue |
over 280 billion yen (2022)
|
| gptkbp:romanization |
gptkb:Taishō_Seiyaku_Kabushiki-gaisha
|
| gptkbp:servesArea |
worldwide
|
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stockSymbol |
4581
|
| gptkbp:type |
public (K.K.)
|
| gptkbp:bfsParent |
gptkb:clarithromycin
|
| gptkbp:bfsLayer |
6
|